PT  - JOURNAL ARTICLE
AU  - Watts, Eleanor L.
AU  - Gonzales, Tomas I.
AU  - Strain, Tessa
AU  - Saint-Maurice, Pedro F.
AU  - Bishop, D. Timothy
AU  - Chanock, Stephen J.
AU  - Johansson, Mattias
AU  - Keku, Temitope O.
AU  - Marchand, Loic Le
AU  - Moreno, Victor
AU  - Newcomb, Polly A.
AU  - Newton, Christina C.
AU  - Pai, Rish K.
AU  - ,
AU  - Purdue, Mark P.
AU  - Ulrich, Cornelia M.
AU  - Smith-Byrne, Karl
AU  - Guelpen, Bethany Van
AU  - Day, Felix R.
AU  - Wijndaele, Katrien
AU  - Wareham, Nicholas J.
AU  - Matthews, Charles E.
AU  - Moore, Steven C.
AU  - Brage, Soren
TI  - Observational and genetic associations between cardiorespiratory fitness and cancer: a UK Biobank and international consortia study
AID  - 10.1101/2023.03.28.23287805
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.03.28.23287805
4099  - http://medrxiv.org/content/early/2023/03/30/2023.03.28.23287805.short
4100  - http://medrxiv.org/content/early/2023/03/30/2023.03.28.23287805.full
AB  - Importance The association of cardiorespiratory fitness with cancer risk is not clear.Objective To investigate whether fitness is associated with the risk of diagnosis of common cancers.Design, setting, and participants In observational analyses, we used multivariable-adjusted Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for risk of cancer in a subset of UK Biobank participants who completed a submaximal fitness test in 2009-12 (N=72,572). In secondary analyses, we used a two-sample Mendelian randomization (MR) framework, with genetically predicted fitness as an instrumental variable derived from UK Biobank study participants and genetic cancer data from international consortia. Odds ratios (ORs) were estimated using the inverse-variance weighted method.Relationships between fitness and cancer may be partially mediated by adiposity, and therefore associations were estimated with and without adjustment for adiposity.Exposures Estimated maximal cardiorespiratory fitness (ml O2⋅min-1⋅kg-1 total-body mass and ml O2⋅min-1⋅kg-1 fat-free mass).Main outcomes and measures Diagnosis of lung, colon, rectal, endometrial, female breast, and prostate cancer. MR analyses additionally included pancreatic and renal cancers.Results After a median of 11 years of follow-up, 4,290 cancers of interest were diagnosed. A 3.5 ml O2⋅min-1⋅kg-1 total-body mass increase in fitness (approximately 0.5 standard deviation (SD)) was associated with lower risks of endometrial (HR=0.81, 95% CI 0.73-0.89), colorectal (0.94, 0.90-0.99), and breast cancer (0.96, 0.92-0.99). In MR analyses, higher levels of genetically predicted fitness were associated with a lower risk of breast cancer (OR per genetically predicted 0.5 SD increase in ml O2⋅min-1⋅kg-1 fat-free mass=0.92, 95% CI 0.86-0.98), including estrogen receptor (ER)+ (0.91, 0.84-0.99) and ER-(0.88, 0.80-0.97) subtypes. After adjusting for body fat, both the observational and genetic associations were attenuated.Conclusions and relevance Higher fitness levels may reduce risks of endometrial, colorectal, and breast cancer, though relationships with adiposity are complex and may mediate these relationships. Aiming to increase fitness, including via changes in body composition, may be an effective strategy for cancer prevention.KEY POINTS Question: Is cardiorespiratory fitness associated with subsequent risk of cancer diagnosis?Findings: In a prospective cohort study of 73,000 cancer-free participants who completed a submaximal fitness test, we report that higher fitness levels were associated with lower risks of endometrial, colorectal, and breast cancer. Using two-sample Mendelian randomization methods we also found an inverse association with breast cancer. Associations were attenuated following adjustment for adiposity.Meaning: Higher fitness may be associated with reduced risk of certain cancer sites. Aiming to increase fitness, including via changes in body composition, may be an effective strategy for cancer prevention. The role of adiposity in mediating the relationship between fitness and cancer risk is not fully understood, and further research is needed to explore this complex relationship.Competing Interest StatementThe authors have declared no competing interest.Funding StatementEW, SM, CM, PSM are supported by the Intramural Research Program of the National Institutes of Health (NIH). NW, TS, FRD, KW, TG and SB are supported by UK Medical Research Council [grant numbers MC_UU_00006/1, MC_UU_00006/2 and MC_UU_00006/4]. NW and SB are supported by the NIHR Biomedical Research Centre in Cambridge (IS-BRC-1215-20014). The NIHR Cambridge Biomedical Research Centre (BRC) is a partnership between Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge, funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank had obtained ethics approval from the North West Multi-centre Research Ethics Committee which covers the UK (approval number: 11/NW/0382) and had obtained informed consent from all participants. The UK Biobank approved an application for use of the data (ID 408 and 9905)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe UK Biobank is an open-access resource and bona fide researchers can apply to use the UK Biobank dataset by registering and applying at http://ukbiobank.ac.uk/register-apply/. Further information is available from the corresponding author upon request. For genetic cancer data, summary GWAS statistics are publicly available for breast (https://bcac.ccge.medschl.cam.ac.uk/), endometrial (https://www.ebi.ac.uk/gwas/studies/GCST006464), ovarian (https://ocac.ccge.medschl.cam.ac.uk) and prostate (overall only) (http://practical.icr.ac.uk/). Data for renal cell carcinoma and pancreatic cancer were accessed via dbGaP; Study Accession: phs000206.v3.p2 and phs000648.v1.p1; project reference 9314 (https://www.ncbi.nlm.nih.gov/gap/). Summary genetic data for aggressive prostate cancer (http://practical.icr.ac.uk/), lung cancer (https://ilcco.iarc.fr/) and colorectal cancer (https://research.fredhutch.org/peters/en/genetics-and-epidemiology-of-colorectal-cancer-consortium.html) are not currently publicly available but may be made available upon application, see respective websites for details.